Insider Trading Alert - ARCP, DECK, TPLM, BMRN And KLAC Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 6, 2014, 102 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1.10 to $7,496,280.00.

Highlighted Stocks Traded by Insiders:

American Realty Capital Properties Inc Clas (ARCP) - FREE Research Report

Bowman Scott J. who is Director at American Realty Capital Properties Inc Clas bought 10,000 shares at $12.75 on Jan. 6, 2014. Following this transaction, the Director owned 10,000 shares meaning that the stake was reduced by 100% with the 10,000-share transaction.

The shares most recently traded at $12.78, up $0.03, or 0.23% since the insider transaction. Historical insider transactions for American Realty Capital Properties Inc Clas go as follows:

  • 4-Week # shares bought: 27,500
  • 12-Week # shares bought: 72,500
  • 24-Week # shares bought: 277,500

The average volume for American Realty Capital Properties Inc Clas has been 5.4 million shares per day over the past 30 days. American Realty Capital Properties Inc Clas has a market cap of $2.4 billion and is part of the financial sector and real estate industry. Shares are down 0.24% year-to-date as of the close of trading on Monday.

American Realty Capital Properties, Inc. owns and acquires single tenant, freestanding commercial real estate that is net leased on a medium-term basis, primarily to investment grade credit rated and other creditworthy tenants. The company principally invests in retail and office properties. The stock currently has a dividend yield of 7.28%. Currently there are 4 analysts that rate American Realty Capital Properties Inc Clas a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on ARCP - FREE

TheStreet Quant Ratings rates American Realty Capital Properties Inc Clas as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and notable return on equity. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, poor profit margins and a generally disappointing performance in the stock itself. Get the full American Realty Capital Properties Inc Clas Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Deckers Outdoor Corporation (DECK) - FREE Research Report

George Thomas who is Cfo at Deckers Outdoor Corporation sold 2,522 shares at $83.94 on Jan. 6, 2014. Following this transaction, the Cfo owned 91,712 shares meaning that the stake was reduced by 2.68% with the 2,522-share transaction.

The shares most recently traded at $89.78, up $5.84, or 6.5% since the insider transaction. Historical insider transactions for Deckers Outdoor Corporation go as follows:

  • 4-Week # shares sold: 6,500
  • 12-Week # shares sold: 41,300
  • 24-Week # shares sold: 46,377

The average volume for Deckers Outdoor Corporation has been 1.5 million shares per day over the past 30 days. Deckers Outdoor Corporation has a market cap of $3.0 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are up 4.18% year-to-date as of the close of trading on Monday.

Deckers Outdoor Corporation engages in the design, manufacture, and marketing of footwear and accessories for outdoor activities and casual lifestyle use for men, women, and children in the United States and internationally. The company has a P/E ratio of 30.8. Currently there are 7 analysts that rate Deckers Outdoor Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DECK - FREE

TheStreet Quant Ratings rates Deckers Outdoor Corporation as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Deckers Outdoor Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Triangle Petroleum (TPLM) - FREE Research Report

Hill Peter J who is Director at Triangle Petroleum sold 10,000 shares at $8.22 on Jan. 6, 2014. Following this transaction, the Director owned 264,063 shares meaning that the stake was reduced by 3.65% with the 10,000-share transaction.

The shares most recently traded at $8.05, down $0.17, or 2.11% since the insider transaction. Historical insider transactions for Triangle Petroleum go as follows:

  • 4-Week # shares sold: 22,500
  • 12-Week # shares sold: 22,500
  • 24-Week # shares sold: 78,833

The average volume for Triangle Petroleum has been 1.6 million shares per day over the past 30 days. Triangle Petroleum has a market cap of $697.0 million and is part of the basic materials sector and energy industry. Shares are down 3.85% year-to-date as of the close of trading on Monday.

Triangle Petroleum Corporation engages in the acquisition, exploration, development, and production of unconventional shale oil and natural gas resources in the Bakken Shale and Three Forks formations in the Williston Basin of North Dakota and Montana. The company has a P/E ratio of 37.0. Currently there are 6 analysts that rate Triangle Petroleum a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on TPLM - FREE

TheStreet Quant Ratings rates Triangle Petroleum as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, impressive record of earnings per share growth and compelling growth in net income. However, as a counter to these strengths, we find that we feel that the company's cash flow from its operations has been weak overall. Get the full Triangle Petroleum Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Biomarin Pharmaceutical (BMRN) - FREE Research Report

Fuchs Henry J who is EVP, Chief Medical Officer at Biomarin Pharmaceutical sold 916 shares at $68.97 on Jan. 6, 2014. Following this transaction, the EVP, Chief Medical Officer owned 42,350 shares meaning that the stake was reduced by 2.12% with the 916-share transaction.

The shares most recently traded at $67.96, down $1.01, or 1.48% since the insider transaction. Historical insider transactions for Biomarin Pharmaceutical go as follows:

  • 4-Week # shares sold: 2,900
  • 12-Week # shares sold: 2,999
  • 24-Week # shares sold: 2,999

The average volume for Biomarin Pharmaceutical has been 1.6 million shares per day over the past 30 days. Biomarin Pharmaceutical has a market cap of $9.8 billion and is part of the health care sector and drugs industry. Shares are down 4.62% year-to-date as of the close of trading on Monday.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Currently there are 12 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BMRN - FREE

TheStreet Quant Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Biomarin Pharmaceutical Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

KLA-Tencor Corporation (KLAC) - FREE Research Report

Kirloskar Virendra A who is SVP & Chief Accounting Officer at KLA-Tencor Corporation sold 152 shares at $63.36 on Jan. 6, 2014. Following this transaction, the SVP & Chief Accounting Officer owned 297 shares meaning that the stake was reduced by 33.85% with the 152-share transaction.

Higgins Bren D. who is EVP & Chief Financial Officer at KLA-Tencor Corporation sold 196 shares at $63.36 on Jan. 6, 2014. Following this transaction, the EVP & Chief Financial Officer owned 0 shares meaning that the stake was reduced by 100% with the 196-share transaction.

The shares most recently traded at $62.26, down $1.10, or 1.77% since the insider transaction. Historical insider transactions for KLA-Tencor Corporation go as follows:

  • 4-Week # shares sold: 6,967
  • 12-Week # shares sold: 6,967
  • 24-Week # shares sold: 74,615

The average volume for KLA-Tencor Corporation has been 1.2 million shares per day over the past 30 days. KLA-Tencor Corporation has a market cap of $10.6 billion and is part of the technology sector and electronics industry. Shares are down 3.26% year-to-date as of the close of trading on Monday.

KLA-Tencor Corporation engages in design, manufacture, and marketing of process control and yield management solutions for the semiconductor and related nanoelectronics industries worldwide. The stock currently has a dividend yield of 2.84%. The company has a P/E ratio of 20.7. Currently there are 7 analysts that rate KLA-Tencor Corporation a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on KLAC - FREE

TheStreet Quant Ratings rates KLA-Tencor Corporation as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full KLA-Tencor Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug